Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin
GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that new gene expression data based on a validated method from TATAA Biocenter AB, which is significantly more sensitive than the pre-commercial method, shows that a larger proportion of patients, i.e. those with low ABCC3 expression, could have significant better effect of arfolitixorin than currently used prodrugs (leucovorin) on PFS and ultimately on overall survival.The data from the optimized gene expression method validated by TATAA Biocenter AB, compared